Recently, we introduced a novel treatment of Alzheimer's disease (AD) consisting of the use of photobiomodulation (PBM) coupled with a static magnetic field . The efficiency of this approach was evidenced on a model of mice affected by a neurotoxic agent (Amyloid-β(25-35)).
In this communication, we will present recent results using this approach at the scale of neural cells in culture, as an attempt to enhance the benefit of light starting from a much simpler model than an entire mammalian organism. We will highlight the interest of using imaging instead of ensemble fluorescence measurements, and comment on parameters such as the PBM wavelength, fluence and glutamate concentration.
|